SCYX News & Events

SCYNEXIS announced that the first participants have been dosed in a Phase 1 single ascending dose and multiple ascending dose trial evaluating the intravenous formulation of its second-generation triterpenoid antifungal therapy, SCY-247, which is being developed as a treatment for invasive candidiasis and as a prophylaxis therapy for invasive fungal disease. Results from this trial are expected in 2026.

CERo Therapeutics Holdings (CERO) announces the appointment of Eric Francois to the Company's Board of Directors. Formerly, he served as CFO of SCYNEXIS (SCYX).

Scynexis announced that the U.S. Food and Drug Administration, FDA, has granted the Company Qualified Infectious Disease Product, QIDP, and Fast Track Designations, FTD, for its second-generation triterpenoid antifungal therapy, SCY-247. In 2026, the Company expects to initiate a Phase 1 study of SCY-247 with the IV formulation as well as a Phase 2 study with the oral formulation in invasive candidiasis. Scynexis also aims to release proof-of -concept data for the oral formulation of SCY-247 in IC in 2026. Considering the differentiated attributes of SCY-247 and its potential role to counter health security threats posed by antifungal resistance development, the company will also continue exploring potential non-dilutive funding opportunities to further support this program.